-+ 0.00%
-+ 0.00%
-+ 0.00%

ALNYLAM PHARMACEUTICALS - PHASE 1B RESULTS SHOW 60-64% MEAN REDUCTION OF CSF MUTANT HUNTINGTIN AT MONTH 3

路透·10/23/2026 07:45:00

请登录查看新闻详情